U.S. markets open in 6 hours 20 minutes

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.36-0.78 (-10.92%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close7.14
Bid0.00 x 4000
Ask0.00 x 4000
Day's Range6.26 - 6.94
52 Week Range1.08 - 24.90
Avg. Volume15,504,283
Market Cap748.998M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-0.37
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 09, 2012
1y Target Est17.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more

    Vaxart, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 2, 2021 / Vaxart, Inc. (NASDAQ:VXRT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 2, 2021 at 4:30 PM Eastern Time.

  • VAXART, INC. (VXRT) Moves 5.6% Higher: Will This Strength Last?

    VAXART, INC. (VXRT) Moves 5.6% Higher: Will This Strength Last?

    VAXART, INC. (VXRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

  • Could Vaxart Be a Millionaire-Maker Stock?
    Motley Fool

    Could Vaxart Be a Millionaire-Maker Stock?

    Vaxart (NASDAQ: VXRT) made some investors quite wealthy in 2020. Its shares skyrocketed more than 1,500% on increasing enthusiasm about its tablet COVID-19 vaccine program. Vaxart's big sell-off in February underscores the main hurdle the company must jump to deliver huge returns for investors.